| Literature DB >> 25801032 |
Dewen You1, Junping Xin2, Andrew Volk3, Wei Wei2, Rachel Schmidt2, Gina Scurti4, Sucha Nand5, Eun-Kyoung Breuer6, Paul C Kuo4, Peter Breslin7, Ameet R Kini8, Michael I Nishimura4, Nancy J Zeleznik-Le9, Jiwang Zhang10.
Abstract
Mutations and inactivation of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) are observed in 15%-25% of cases of human T cell acute lymphoblastic leukemia (T-ALL). Pten deletion induces myeloproliferative disorders (MPDs), acute myeloid leukemia (AML), and/or T-ALL in mice. Previous studies attributed Pten-loss-related hematopoietic defects and leukemogenesis to excessive activation of phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signaling. Although inhibition of this signal dramatically suppresses the growth of PTEN-null T-ALL cells in vitro, treatment with inhibitors of this pathway does not cause a complete remission in vivo. Here, we report that focal adhesion kinase (Fak), a protein substrate of Pten, also contributes to T-ALL development in Pten-null mice. Inactivation of the FAK signaling pathway by either genetic or pharmacologic methods significantly sensitizes both murine and human PTEN-null T-ALL cells to PI3K/AKT/mTOR inhibition when cultured in vitro on feeder layer cells or a matrix and in vivo.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25801032 PMCID: PMC7001526 DOI: 10.1016/j.celrep.2015.02.056
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423